Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized double-blind placebo-controlled study of ANB019 in EGFRi/MEKi-associated acneiform rash
2020-003494-22Phase 2Terminated
- Sponsor
- AnaptysBio, Inc.
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acneiform rash comparing ANB019 with Placebo (2 arms). Primary endpoint: Change from baseline in facial inflammatory lesion count at Week 8. Started Nov 2020; status: terminated.
02
Drugs
imsidolimab
03
Conditions
acneiform rash
Beyond the preview
Go deeper on 2020-003494-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003494-22.